☰

Jerome T. Higgs, Ph.D. - Publications

Affiliations: 
2013 Pathology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Pathology, Oncology
Tree Info Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD, Ponnazhagan S. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Advances. 1: 2375-2385. PMID 29296887 DOI: 10.1182/Bloodadvances.2017007310  0.601
2017 Chanda D, Hensel JA, Higgs JT, Grover R, Kaza N, Ponnazhagan S. Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus. Genes. 8. PMID 28926997 DOI: 10.3390/Genes8090232  0.406
2015 Higgs JT, Jarboe JS, Lee JH, Chanda D, Lee CM, Deivanayagam C, Ponnazhagan S. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. Molecular Cancer Research : McR. 13: 819-27. PMID 25636966 DOI: 10.1158/1541-7786.Mcr-14-0492  0.577
2013 Higgs JT. Abstract 2240: Structural variant of osteoprotegerin lacking TRAIL binding for therapeutic bone remodeling in osteolytic malignancies. Cancer Research. 73: 2240-2240. DOI: 10.1158/1538-7445.Am2013-2240  0.522
2012 Higgs JT, Jarboe J, Ponnazhagan S. Abstract 4943: Genetically engineered osteoprotegerin for multiple myeloma osteolytic bone damage Cancer Research. 72: 4943-4943. DOI: 10.1158/1538-7445.Am2012-4943  0.521
2011 Higgs JT, Jarboe J, Ponnazhagan S. Abstract 3391: Regenerative stem cell therapy for multiple myeloma osteolytic bone damage Cancer Research. 71: 3391-3391. DOI: 10.1158/1538-7445.Am2011-3391  0.601
Show low-probability matches.